CRISPR Strategies Against Antimicrobial-Resistant Bacteria
Author Information
Author(s): de la Fuente Tagarro Carlos, Martín-González Diego, De Lucas Andrea, Bordel Sergio, Santos-Beneit Fernando
Primary Institution: University of Valladolid
Hypothesis
Can CRISPR/Cas systems effectively combat antimicrobial resistance in bacteria?
Conclusion
CRISPR/Cas systems show promise in treating antimicrobial resistance and discovering new antibiotics.
Supporting Evidence
- CRISPR/Cas systems can target plasmids or bacterial chromosomes of antimicrobial-resistant bacteria.
- Over 95% of bacterial and fungal natural products remain uncharacterized, presenting opportunities for antibiotic discovery.
- CRISPR/Cas has been used to activate silent biosynthetic gene clusters in Streptomyces, leading to new antibiotic discoveries.
Takeaway
Scientists are using a tool called CRISPR to help fight germs that don't respond to medicine anymore, and to find new medicines.
Methodology
The review discusses various CRISPR/Cas applications in antimicrobial resistance management and antibiotic discovery.
Limitations
The variability in CRISPR/Cas effects is influenced by factors such as bacterial species and environmental conditions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website